¶ Accelerating COVID-19 Therapeutic Interventions and Vaccines
.png)
This page has moved! Click here to view the most up-to-date version of this page on the White Rose Wiki.
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a public-private partnership created to develop a coordinated research strategy for prioritizing and speeding up development of COVID-19 vaccines and pharmaceutical products. ACTIV is led by the Foundation for the National Institutes of Health (FNIH).[1]
¶ History
ACTIV was announced by the National Institutes of Health on April 17, 2020.[1:1]
Starting in June 2020, Robert Malone has been an invited participant of the ACTIV Therapeutics Clinical Working Group.[2]
On June 8, 2021, the ACTIV-6 study began examining repurposed drugs to treat COVID-19. The four drugs included in the study are ivermectin, fluvoxamine, fluticasone and montelukast.[3]
¶ Participants
ACTIV is a collaboration between a number of agencies, corporations and non-profit organizations:[1:2]
- AbbVie
- Amgen
- AstraZeneca
- Bill & Melinda Gates Foundation
- Biomedical Advanced Research and Development Authority (BARDA)
- Bristol-Myers Squibb
- Centers for Disease Control and Prevention (CDC)
- Dewpoint Therapeutics
- Eisai
- Eli Lilly
- European Medicines Agency (EMA)
- Food and Drug Administration (FDA)
- Foundation for the National Institutes of Health (FNIH)
- Fred Hutchinson Cancer Center
- Genentech
- Gilead Sciences
- GlaxoSmithKline (GSK)
- HHS-DOD COVID-19 Countermeasures Acceleration Group (CAG) (CAG) (formerly Operation Warp Speed)
- Johnson & Johnson
- Merck
- Moderna
- National Institutes of Health (NIH)
- Novartis
- Novavax
- Pfizer
- Rhythm Therapeutics
- Roche
- RTI International
- Sanofi
- Takeda Pharmaceuticals
- United States Department of Defense (DOD)
- United States Department of Veterans Affairs (VA)
- Vir Biotechnology
¶ Executive Committee
The ACTIV Executive Committee is made up of representatives from various agencies of the U.S. government and pharmaceutical companies.[4]
| Name | Organization | Role |
|---|---|---|
| Larry Tabak | National Institutes of Health (NIH) | Co-Chair |
| William Pao | Roche | Co-Chair |
| Gary Disbrow | Biomedical Advanced Research and Development Authority (BARDA) | Member |
| Mikael Dolsten | Pfizer | Member |
| Anthony Fauci | National Institute of Allergy and Infectious Diseases (NIAID) | Member |
| Gary Gibbons | National Institutes of Health (NIH) | Member |
| Peter Marks | Food and Drug Administration (FDA) | Member |
| Gary Dubin | Takeda Pharmaceuticals | Member |
| Janet Woodcock | Food and Drug Administration (FDA) | Member |
¶ Preclinical Working Group
ACTIV's pre-clinical working group includes:[5]
| Name | Organization | Role |
|---|---|---|
| Christine Colvis | National Center for Advancing Translational Sciences | Co-Chair |
| John Young | Roche | Member |
| Peter Adams | United States Department of Health of Human Services | Member |
| Annaliesa Anderson | Pfizer | Member |
| James Anderson | National Institutes of Health | Member |
| Ralph Baric | University of North Carolina at Chapel Hill | Member |
| Kara Carter | Dewpoint Therapeutics | Member |
| Marc Charette | National Heart, Lung, and Blood Institute | Member |
| Tomas Cihlar | Gilead Sciences | Member |
| Michael Diamond | Washington University School of Medicine in St. Louis | Member |
| Ken Duncan | Bill & Melinda Gates Foundation | Member |
| Prabhavathi Fernandes | National Biodefense Science Board | Member |
| Joshua Fessel | National Heart, Lung, and Blood Institute | Member |
| Clint Florence | National Institute of Allergy and Infectious Diseases | Member |
| Greg Gatto | RTI International | Member |
| Jay Grobler | Merck | Member |
| Nancy Haigwood | Oregon National Primate Research Center; Oregon Health & Science University | Member |
| Judith Hewitt | National Institute of Allergy and Infectious Diseases | Member |
| Sheri Hild | National Institutes of Health | Member |
| Samantha Jonson | National Center for Advancing Translational Sciences | Member |
| Isis Kanevsky | Pfizer | Member |
| Kent Lloyd | University of California, Davis | Member |
| Joanne Lumsden | National Center for Advancing Translational Sciences | Member |
| Cat Lutz | Jackson Laboratory | Member |
| Stephen Mason | Pfizer | Member |
| Frank Nestle | Sanofi | Member |
| Elizabeth Ottinger | National Center for Advancing Translational Sciences | Member |
| David Payne | GlaxoSmithKline | Member |
| Louise Pitt | United States Army Medical Research Institute of Infectious Diseases | Member |
| Antonello Punturieri | National Heart, Lung, and Blood Institute | Member |
| Srinivas Rao | Sanofi | Member |
| Jay Rappaport | Tulane National Primate Research Center | Member |
| Roland Zahn | Janssen | Member |
¶ Therapeutics Clinical Working Group
Members of the ACTIV Therapeutics Clinical Working Group include:[6]
¶ Clinical Trial Capacity Working Group
The ACTIV Clinical Trial Capacity Working Group includes:[7]
¶ Vaccines Working Group
The ACTIV Vaccines Working Group includes:[8]
¶ TRACE Working Group
¶ Activities
ACTIV has run a series of clinical trials related to COVID-19 vaccines and therapeutics:
¶ External links
ACTIV. National Institutes of Health (NIH). Retrieved April 1, 2022, from http://archive.today/2022.01.11-042823/https://www.nih.gov/research-training/medical-research-initiatives/activ ↩︎ ↩︎ ↩︎
Malone, R. (2021). RWM CV. Squarespace. https://web.archive.org/web/20230621060440/https://static1.squarespace.com/static/550b0ac4e4b0c16cdea1b084/t/60b61dbe39f1e800244e53e4/1622547902895/RWM+CV+1+June+2021+.pdf ↩︎ ↩︎
Naggie, S., National Center for Advancing Translational Sciences (NCATS), & Vanderbilt University Medical Center. (2023, May 4). ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications. ClinicalTrials.gov. https://web.archive.org/web/20230518153157/https://clinicaltrials.gov/ct2/show/NCT04885530 ↩︎
ACTIV Public-Private Partnership. (2022). National Institutes of Health. https://web.archive.org/web/20220402051949/https://www.nih.gov/sites/default/files/research-training/initiatives/activ/activ-org-chart_3.2.22.pdf ↩︎
Preclinical Working Group. (2022, March 8). National Institutes of Health (NIH). http://archive.today/2022.04.02-062343/https://www.nih.gov/research-training/medical-research-initiatives/activ/preclinical-working-group ↩︎
Therapeutics Clinical Working Group. (2022, March 8). National Institutes of Health (NIH). http://archive.today/2023.07.02-204924/https://www.nih.gov/research-training/medical-research-initiatives/activ/therapeutics-clinical-working-group ↩︎
Clinical Trial Capacity Working Group. (2020, December 23). National Institutes of Health (NIH). http://archive.today/2023.07.03-013941/https://www.nih.gov/research-training/medical-research-initiatives/activ/clinical-trial-capacity-working-group ↩︎
Vaccines Working Group. (2021, April 8). National Institutes of Health (NIH). http://archive.today/2023.07.03-024616/https://www.nih.gov/research-training/medical-research-initiatives/activ/vaccines-working-group ↩︎